ES2630037T3 - Suspensión farmacéutica - Google Patents
Suspensión farmacéutica Download PDFInfo
- Publication number
- ES2630037T3 ES2630037T3 ES09768284.3T ES09768284T ES2630037T3 ES 2630037 T3 ES2630037 T3 ES 2630037T3 ES 09768284 T ES09768284 T ES 09768284T ES 2630037 T3 ES2630037 T3 ES 2630037T3
- Authority
- ES
- Spain
- Prior art keywords
- sediment
- volume
- molecular weight
- peg
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007971 pharmaceutical suspension Substances 0.000 title abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 10
- 239000000725 suspension Substances 0.000 abstract description 10
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 5
- 239000004705 High-molecular-weight polyethylene Substances 0.000 abstract description 4
- 239000000375 suspending agent Substances 0.000 abstract description 4
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- -1 polyethylene Polymers 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000013049 sediment Substances 0.000 description 18
- 238000005189 flocculation Methods 0.000 description 6
- 230000016615 flocculation Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- 229920002560 Polyethylene Glycol 3000 Polymers 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12008108P | 2008-12-05 | 2008-12-05 | |
| US120081P | 2008-12-05 | ||
| PCT/US2009/066570 WO2010065730A2 (en) | 2008-12-05 | 2009-12-03 | Pharmaceutical suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2630037T3 true ES2630037T3 (es) | 2017-08-17 |
Family
ID=41562672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09768284.3T Active ES2630037T3 (es) | 2008-12-05 | 2009-12-03 | Suspensión farmacéutica |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9707173B2 (enExample) |
| EP (1) | EP2364137B1 (enExample) |
| JP (1) | JP5661640B2 (enExample) |
| AR (1) | AR074423A1 (enExample) |
| AU (1) | AU2009322355B2 (enExample) |
| CA (1) | CA2745123C (enExample) |
| CY (1) | CY1119038T1 (enExample) |
| DK (1) | DK2364137T3 (enExample) |
| ES (1) | ES2630037T3 (enExample) |
| HR (1) | HRP20170959T1 (enExample) |
| HU (1) | HUE034662T2 (enExample) |
| LT (1) | LT2364137T (enExample) |
| PL (1) | PL2364137T3 (enExample) |
| PT (1) | PT2364137T (enExample) |
| SI (1) | SI2364137T1 (enExample) |
| TW (1) | TW201023912A (enExample) |
| WO (1) | WO2010065730A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011008680A (es) * | 2009-03-03 | 2011-09-08 | Alcon Res Ltd | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. |
| US8912236B2 (en) | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| JP2013535451A (ja) * | 2010-07-21 | 2013-09-12 | アルコン リサーチ， リミテッド | 増強された溶解度特徴を有する薬学的組成物 |
| EP2601187A1 (en) | 2010-08-05 | 2013-06-12 | Conrig Pharma ApS | Deuterated tandospirone derivatives as 5-ht1a receptor agonists |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
| JP6279395B2 (ja) * | 2014-05-01 | 2018-02-14 | 東亜薬品株式会社 | ブリンゾラミド懸濁性点眼液組成物の製造方法 |
| US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
| CN108434116B (zh) * | 2017-02-16 | 2021-05-11 | 人福普克药业（武汉）有限公司 | 贝萨罗汀软胶囊及其制备方法 |
| AU2018298855B2 (en) | 2017-07-14 | 2024-07-18 | Janssen Pharmaceutica Nv | Long-acting formulations |
| GR1009419B (el) * | 2017-11-07 | 2018-12-14 | Φαρματεν Αβεε | Οφθαλμικο φαρμακευτικο σκευασμα που περιεχει εναν συνδυασμο βρινζολαμιδης και βριμονιδινης και μεθοδος για την παρασκευη αυτου |
| TWI798452B (zh) * | 2019-06-17 | 2023-04-11 | 晶碩光學股份有限公司 | 隱形眼鏡產品 |
| CN113018271B (zh) * | 2019-12-25 | 2022-08-09 | 四川科瑞德制药股份有限公司 | 一种坦度螺酮药物组合物及其制备方法和用途 |
| DK3861985T3 (da) | 2020-02-06 | 2023-07-24 | Ocular Therapeutix Inc | Sammensætninger og fremgangsmåder til behandling af øjensygdomme |
| CA3177005A1 (en) | 2020-04-27 | 2021-11-04 | Michael Goldstein | Methods of treating allergic conjunctivitis |
| US20220105100A1 (en) * | 2020-10-05 | 2022-04-07 | Somerset Therapeutics, Llc | Safe brinzolamide and brimonidine compositions with enhanced benzalkonium chloride content |
| US20220105101A1 (en) | 2020-10-05 | 2022-04-07 | Somerset Therapeutics, Llc | Efficient brinzolamide and brimonidine compositions |
| EP4565242A1 (en) * | 2023-05-11 | 2025-06-11 | Akums Drugs And Pharmaceuticals Limited | Benzalkonium chloride free ophthalmic formulation |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856919A (en) * | 1970-06-08 | 1974-12-24 | Burton Parsons Chemicals Inc | Ophthalmic solution |
| US3931319A (en) | 1974-10-29 | 1976-01-06 | Millmaster Onyx Corporation | Capped polymers |
| US4027020A (en) | 1974-10-29 | 1977-05-31 | Millmaster Onyx Corporation | Randomly terminated capped polymers |
| US4409205A (en) | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
| US4407791A (en) | 1981-09-28 | 1983-10-04 | Alcon Laboratories, Inc. | Ophthalmic solutions |
| US4525346A (en) | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4836986A (en) | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| US5037647A (en) | 1988-09-15 | 1991-08-06 | Alcon Laboratories, Inc. | Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride |
| US5461081A (en) | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5145643A (en) | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
| US5206267A (en) | 1991-05-09 | 1993-04-27 | Morton Shulman | Pain controlling composition and method of preparation |
| US5338732A (en) | 1991-06-18 | 1994-08-16 | Bristol-Myers Squibb Company | Megestrol acetate formulation |
| US5932572A (en) | 1992-02-21 | 1999-08-03 | Alcon Laboratories, Inc. | Topical anti-glaucoma compositions |
| US5300287A (en) | 1992-11-04 | 1994-04-05 | Alcon Laboratories, Inc. | Polymeric antimicrobials and their use in pharmaceutical compositions |
| AU668447B2 (en) * | 1993-04-16 | 1996-05-02 | Wakamoto Pharmaceutical Co., Ltd. | Reversible, thermally gelling water-base medicinal composition |
| EP0782850A4 (en) | 1994-10-13 | 1998-03-04 | Wakamoto Pharma Co Ltd | LYOPHILIZED PREPARATION FOR PRODUCING A REVERSIBLE THERMOGELING MEDICINAL WATER-BASED |
| AU718199B2 (en) | 1996-12-13 | 2000-04-06 | Alcon Laboratories, Inc. | Use of low molecular weight amino alcohols in ophthalmic compositions |
| JPH10287552A (ja) | 1997-04-11 | 1998-10-27 | Kobayashi Seiyaku Kogyo Kk | 滅菌されたアシクロビル水性懸濁点眼剤及びその製造方法 |
| ATE225392T1 (de) | 1997-07-29 | 2002-10-15 | Alcon Lab Inc | Konditionierungslösungen für die pflege von harten kontaktlinsen |
| AU6870800A (en) * | 1999-09-06 | 2001-04-10 | Ono Pharmaceutical Co. Ltd. | Preventive and therapeutic agents for eye diseases |
| PT1214056E (pt) | 1999-09-24 | 2004-02-27 | Alcon Inc | Formulacoes em suspensao topica que contem ciprofloxacina e dexametasona |
| WO2001087262A2 (en) * | 2000-05-15 | 2001-11-22 | Pharmacia Italia S.P.A. | Stabilized steroidal suspension |
| JP2004504357A (ja) | 2000-07-26 | 2004-02-12 | アルコン，インコーポレイテッド | ポリマー性懸濁化剤を含有しない薬学的懸濁組成物 |
| JP3450805B2 (ja) * | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | 水性医薬組成物 |
| US20040256749A1 (en) | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
| US6743439B1 (en) * | 2001-06-27 | 2004-06-01 | Alcon, Inc. | Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride |
| BR0212898A (pt) | 2001-09-21 | 2004-10-13 | Alcon Inc | Método de tratamento de infecções do ouvido médio |
| US7001615B1 (en) | 2001-12-07 | 2006-02-21 | Alcon, Inc. | Sustained release ophthalmic, otic and nasal suspension |
| US20050025791A1 (en) | 2002-06-21 | 2005-02-03 | Julius Remenar | Pharmaceutical compositions with improved dissolution |
| PT1638941E (pt) | 2003-05-22 | 2010-08-24 | Abbott Lab | Inibidores de quinases de indazole, benzisoxazole e benzisotiazole |
| US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| CA2562356A1 (en) | 2004-04-08 | 2005-10-27 | Retmed Pty Ltd | Treatment of ophthalmic conditions with mineralcorticoids |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| ES2322200T3 (es) | 2005-05-10 | 2009-06-17 | Alcon, Inc. | Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos. |
| CN101175476B (zh) | 2005-05-10 | 2011-11-16 | 爱尔康公司 | 包含眼科药物、泊洛沙明和二醇张力调节剂的眼科混悬剂，所述组合物用于生产治疗眼科病症的药物的用途 |
| JP2009521493A (ja) | 2005-12-23 | 2009-06-04 | アルコン，インコーポレイテッド | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 |
| US20070173538A1 (en) * | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
| US20070249546A1 (en) | 2006-04-22 | 2007-10-25 | Sawaya Assad S | Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them |
| US8071544B2 (en) * | 2006-12-18 | 2011-12-06 | Althea Technologies, Inc. | Crystallized recombinant human growth factor formulations |
| JP2010534201A (ja) | 2007-07-20 | 2010-11-04 | アルコン，インコーポレイテッド | 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤 |
| PL2072564T3 (pl) | 2007-12-19 | 2013-12-31 | Sika Tech Ag | Jednoskładnikowa, utwardzająca się pod wpływem wilgoci pianka polimerowa |
| JP5155767B2 (ja) | 2008-08-04 | 2013-03-06 | 国立大学法人大阪大学 | ガス検知素子 |
| MX2011008680A (es) | 2009-03-03 | 2011-09-08 | Alcon Res Ltd | Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos. |
-
2009
- 2009-11-19 TW TW098139293A patent/TW201023912A/zh unknown
- 2009-11-30 AR ARP090104602A patent/AR074423A1/es unknown
- 2009-12-03 SI SI200931678A patent/SI2364137T1/sl unknown
- 2009-12-03 EP EP09768284.3A patent/EP2364137B1/en active Active
- 2009-12-03 US US12/630,399 patent/US9707173B2/en active Active
- 2009-12-03 WO PCT/US2009/066570 patent/WO2010065730A2/en not_active Ceased
- 2009-12-03 HU HUE09768284A patent/HUE034662T2/en unknown
- 2009-12-03 CA CA2745123A patent/CA2745123C/en active Active
- 2009-12-03 PT PT97682843T patent/PT2364137T/pt unknown
- 2009-12-03 DK DK09768284.3T patent/DK2364137T3/en active
- 2009-12-03 JP JP2011539693A patent/JP5661640B2/ja active Active
- 2009-12-03 LT LTEP09768284.3T patent/LT2364137T/lt unknown
- 2009-12-03 HR HRP20170959TT patent/HRP20170959T1/hr unknown
- 2009-12-03 AU AU2009322355A patent/AU2009322355B2/en not_active Ceased
- 2009-12-03 PL PL09768284T patent/PL2364137T3/pl unknown
- 2009-12-03 ES ES09768284.3T patent/ES2630037T3/es active Active
-
2017
- 2017-06-29 CY CY20171100695T patent/CY1119038T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20100144719A1 (en) | 2010-06-10 |
| PL2364137T3 (pl) | 2017-09-29 |
| CA2745123C (en) | 2018-11-13 |
| SI2364137T1 (sl) | 2017-07-31 |
| CY1119038T1 (el) | 2018-01-10 |
| WO2010065730A3 (en) | 2011-04-14 |
| EP2364137A2 (en) | 2011-09-14 |
| JP5661640B2 (ja) | 2015-01-28 |
| JP2012511009A (ja) | 2012-05-17 |
| AU2009322355B2 (en) | 2015-11-05 |
| LT2364137T (lt) | 2017-06-26 |
| TW201023912A (en) | 2010-07-01 |
| EP2364137B1 (en) | 2017-03-29 |
| AU2009322355A1 (en) | 2010-06-10 |
| WO2010065730A2 (en) | 2010-06-10 |
| AR074423A1 (es) | 2011-01-19 |
| HUE034662T2 (en) | 2018-02-28 |
| HRP20170959T1 (hr) | 2017-09-22 |
| DK2364137T3 (en) | 2017-07-10 |
| PT2364137T (pt) | 2017-07-10 |
| US9707173B2 (en) | 2017-07-18 |
| CA2745123A1 (en) | 2010-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2630037T3 (es) | Suspensión farmacéutica | |
| Tao et al. | Injectable chitosan-based thermosensitive hydrogel/nanoparticle-loaded system for local delivery of vancomycin in the treatment of osteomyelitis | |
| Vigani et al. | Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes | |
| Ouyang et al. | A facile and general method for synthesis of antibiotic-free protein-based hydrogel: Wound dressing for the eradication of drug-resistant bacteria and biofilms | |
| Wang et al. | Antibacterial effect of chitosan and its derivative on Enterococcus faecalis associated with endodontic infection | |
| Chang et al. | Liposomal dexamethasone–moxifloxacin nanoparticle combinations with collagen/gelatin/alginate hydrogel for corneal infection treatment and wound healing | |
| Zhou et al. | Development of fish collagen/bioactive glass/chitosan composite nanofibers as a GTR/GBR membrane for inducing periodontal tissue regeneration | |
| Geilich et al. | Superparamagnetic iron oxide-encapsulating polymersome nanocarriers for biofilm eradication | |
| Chaurasia et al. | Nanomedicine approaches for corneal diseases | |
| Cassano et al. | Gel-based materials for ophthalmic drug delivery | |
| González-Sánchez et al. | Silver nanoparticle based antibacterial methacrylate hydrogels potential for bone graft applications | |
| Khalil et al. | Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: In vitro, ex vivo and in vivo evaluation | |
| He et al. | Development of an antimicrobial peptide-loaded mineralized collagen bone scaffold for infective bone defect repair | |
| Zhang et al. | Efficient induction of antimicrobial activity with vancomycin nanoparticle-loaded poly (trimethylene carbonate) localized drug delivery system | |
| Goncalves et al. | Macrophage response to chitosan/poly-(γ-glutamic acid) nanoparticles carrying an anti-inflammatory drug | |
| Abbas et al. | Nanoparticles loaded thermoresponsive in situ gel for ocular antibiotic delivery against bacterial keratitis | |
| Pakzad et al. | Thermosensitive hydrogel for periodontal application: In vitro drug release, antibacterial activity and toxicity evaluation | |
| Jiang et al. | Cartilage targeting therapy with reactive oxygen species-responsive nanocarrier for osteoarthritis | |
| Santos et al. | Antibacterial performance of a PCL–PDMAEMA Blend nanofiber-based scaffold enhanced with immobilized silver nanoparticles | |
| Sahal et al. | Electrospun essential oil-polycaprolactone nanofibers as antibiofilm surfaces against clinical Candida tropicalis isolates | |
| CN117624172B (zh) | 一种有机分子笼、有机分子笼纳米酶滴眼液及其制备方法 | |
| Cho et al. | In‐vitro evaluation of a ciprofloxacin‐and ivacaftor‐coated sinus stent against Pseudomonas aeruginosa biofilms | |
| Jia et al. | Development of a Doxycycline Hydrochloride‐Loaded Electrospun Nanofibrous Membrane for GTR/GBR Applications | |
| Munir et al. | Controllably biodegradable hydroxyapatite nanostructures for cefazolin delivery against antibacterial resistance | |
| Park et al. | An injectable, electrostatically interacting drug depot for the treatment of rheumatoid arthritis |